Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sedat Sen

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Applied Psychological Measurement|June 4, 2019
Model Selection for Multilevel Mixture Rasch ModelsSedat Sen, Allan S Cohen, Seock-Ho Kim
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 27, 2017
Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosisCavit Boz, Murat Terzi, Serap Zengin Karahan, et al.
Cutaneous and Ocular Toxicology|February 19, 2014
Phenobarbital-induced pellagra resulted in deathEsra Pancar Yuksel, Sedat Sen, Fatma Aydin, et al.
Clinical Neurology and Neurosurgery|August 10, 2020
Methylprednisolone Concentrations in Breast Milk and Serum of Patients with Multiple Sclerosis Treated with IV Pulse MethylprednisoloneSerap Zengin Karahan, Cavit Boz, Murat Terzi, et al.
Scientific Reports|October 21, 2025
Peripheral cytokine levels in patients with idiopathic parkinson's disease undergoing subthalamic nucleus deep brain stimulationErsoy Kocabıcak, Sedat Sen, Hafize Uzun, et al.
Multiple Sclerosis and Related Disorders|April 30, 2026
Beyond serology: clinical and prognostic determinants in patients with dual AQP4-IgG and MOG-IgG seropositivityIpek Gungor Dogan, Sedat Sen, Damla Cetinkaya Tezer, et al.
Multiple Sclerosis and Related Disorders|September 7, 2023
Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatmentSedat Sen, Asli Tuncer, Murat Terzi, et al.
Multiple Sclerosis and Related Disorders|October 18, 2024
Corrigendum to "Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment" [Multiple Sclerosis and Related Disorders, Volume 79, November 2023, https://doi.org/10.1016/j.msard.2023.104949]Sedat Sen, Asli Tuncer, Murat Terzi, et al.
Multiple Sclerosis and Related Disorders|April 2, 2018
Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trialSerkan Ozakbas, Recai Turkoglu, Yusuf Tamam, et al.
Multiple Sclerosis and Related Disorders|May 17, 2021
A comprehensive assessment of patient experience and disease-related awareness in multiple sclerosis: A questionnaire-based nation-wide survey in TurkeySerkan Demir, Melih Tutuncu, Cihat Uzunkopru, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Applied Psychological Measurement|June 4, 2019
Model Selection for Multilevel Mixture Rasch ModelsSedat Sen, Allan S Cohen, Seock-Ho Kim
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 27, 2017
Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosisCavit Boz, Murat Terzi, Serap Zengin Karahan, et al.
Cutaneous and Ocular Toxicology|February 19, 2014
Phenobarbital-induced pellagra resulted in deathEsra Pancar Yuksel, Sedat Sen, Fatma Aydin, et al.
Clinical Neurology and Neurosurgery|August 10, 2020
Methylprednisolone Concentrations in Breast Milk and Serum of Patients with Multiple Sclerosis Treated with IV Pulse MethylprednisoloneSerap Zengin Karahan, Cavit Boz, Murat Terzi, et al.
Scientific Reports|October 21, 2025
Peripheral cytokine levels in patients with idiopathic parkinson's disease undergoing subthalamic nucleus deep brain stimulationErsoy Kocabıcak, Sedat Sen, Hafize Uzun, et al.
Multiple Sclerosis and Related Disorders|April 30, 2026
Beyond serology: clinical and prognostic determinants in patients with dual AQP4-IgG and MOG-IgG seropositivityIpek Gungor Dogan, Sedat Sen, Damla Cetinkaya Tezer, et al.
Multiple Sclerosis and Related Disorders|September 7, 2023
Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatmentSedat Sen, Asli Tuncer, Murat Terzi, et al.
Multiple Sclerosis and Related Disorders|October 18, 2024
Corrigendum to "Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment" [Multiple Sclerosis and Related Disorders, Volume 79, November 2023, https://doi.org/10.1016/j.msard.2023.104949]Sedat Sen, Asli Tuncer, Murat Terzi, et al.
Multiple Sclerosis and Related Disorders|April 2, 2018
Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trialSerkan Ozakbas, Recai Turkoglu, Yusuf Tamam, et al.
Multiple Sclerosis and Related Disorders|May 17, 2021
A comprehensive assessment of patient experience and disease-related awareness in multiple sclerosis: A questionnaire-based nation-wide survey in TurkeySerkan Demir, Melih Tutuncu, Cihat Uzunkopru, et al.
Pageof 3